Umbilical cord blood (UCB) is an attractive potential alternative to bone marrow (BM) as a source of hematopoietic progenitor cells since the number of progenitors in UCB is similar or even greater than that in normal BM. It was the aim of the present study to analyze the degree of immaturity of UCB progenitor cells. UCB mononuclear (MNC) and/or CD34 + cells were tested for surface antigen phenotype, expression of cytokines receptor, effect of stem cell factor (SCF) on colony growth, resistance to mafosfamide and replating potential. We have found that 34.9 ± 3.4% and 77.9 ± 2.6% of UCB CD34
Introduction
Umbilical cord blood (UCB) has been used as a source of hematopoietic stem cells for clinical transplantation, and is proving to be an acceptable alternative to bone marrow (BM). [1] [2] [3] Studies are under way to determine the feasibility of UCB banking for use in unrelated transplants. [3] [4] [5] [6] However, the major concern for future transplant application in adult patients has been related to the low number of progenitor cells that could be obtained by a single UCB collection. Several studies suggested that UCB contains a higher proportion of hematopoietic progenitor cells as compared to adult BM [7] [8] [9] and therefore the lower number of nucleated cells, present in a single collection, might be compensated by a higher proportion of primitive cells. Since the proliferation of hematopoietic cells is dependent on the presence of hematopoietic cytoCorrespondence: C Almici, Cattedra di Ematologia, Università di Parma, Via Gramsci 14, I-43100 Parma, Italy; Fax: 39 521 292765 Received 17 October 1996; accepted 3 September 1997 kines, 10 the ex vivo expansion potential of UCB has been examined. 8, 9, 11 Recently, highly purified CD34 + CD45RA low -CD71 low UCB cells have been reported to possess a much higher ex vivo proliferative potential in comparison to adult BM cells. 12 Moreover, CD34 + CD38 low stem cells purified from BM, UCB and fetal liver have been demonstrated to differ in replicative capacity as determined by the length of their telomeric DNA. 13 The c-kit receptor and its ligand, stem cell factor (SCF), have been reported to play fundamental roles in the development and differentiation of primitive and committed hematopoietic progenitor cells. 14, 15 Moreover, the development of monoclonal antibodies for the c-kit receptor or alternatively the measurement of direct growth binding has provided the opportunity to further investigate the role and expression of ckit during hematopoietic cell development. 16, 17 In fact, stagerelated expression of c-kit protein has been reported in murine 18 and, more recently, in human BM progenitor cells. 19, 20 The aim of our study was to investigate the characteristics of UCB progenitor cells by means of antigenic phenotype receptors' expression of early-acting cytokines, effect of SCF on colony growth, resistance to mafosfamide treatment and replating potential.
Materials and methods

Cell preparation
Human UCB from healthy full-term neonates were collected with institutional review board approval and maternal consent. Mononuclear (MNC) cells (n = 11; cellularity 118 ± 13.4 × 10 6 ) were obtained by a two-step separation procedure by sedimentation over poligeline (Emagel; Behringwerke, Marburg, Germany), followed by separation over Ficoll/Hypaque gradient (F/H d = 1077 g/ml, Sigma Chemical, St Louis, MO, USA), as previously described.
21
CD34
+ cells (n = 7) were selected from MNC cells using the MiniMACS immunomagnetic separation device (MACS, Miltenyi Biotec, Germany) as described elsewhere. 22 Characterization of growth factor receptor distribution
+ cells (n = 7) were assayed for the presence of receptors for SCF, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), as described elsewhere. 20 Briefly, 1 × 10 5 cells were washed twice and incubated with 100 ng of biotinylated SCF or with streptavidin phycoerythrinconjugated IL-3 and GM-CSF (R&D Systems, Minneapolis, MN, USA) for 60 min on ice. After incubation, the cells were washed twice in 2 ml of RDFI wash buffer (R&D Systems) and incubated, when needed, with 100 ng avidin-fluorescein for Immunofluorescence analysis Unseparated (n = 5) and CD34
+ cells (n = 7) were counted, their concentration adjusted to 0.5 × 10 6 /ml and their surface antigen phenotype determined by immunofluorescence analysis. Cells were incubated for 30 min on ice with specific monoclonal antibodies. Double staining was performed using phycoerythrin (PE)-conjugated anti-CD34 antibody (HPCA-2) associated with either fluorescein (FITC)-conjugated anti-CD38, anti-HLA-DR or anti-CD45RA (Becton Dickinson). To evaluate the contamination of CD34 − cells, double staining with anti-CD34 PE and anti-CD45 FITC was performed on the positively selected CD34 population. Each fluorescence analysis included an isotypic double negative control. On unseparated samples the immunofluorescence analysis was performed on CD34 cells positively gated, as described elsewhere. 23 Briefly, a first gate was drawn on a plot of FSC vs SSC to include the lympho-monocyte region; a second gate was then drawn around CD34
+ cells on a plot of anti-CD45 FITC vs anti-CD34 PE. With both gates activated at least 5000 CD34 + cells were acquired. Three-color analysis was performed in three different experiments in which selected CD34 + cells were incubated with PE-conjugated anti-CD34 (HPCA-2), PerCP-conjugated anti-HLA-DR and with avidin-FITC biotinylated SCF. Matching conjugated isotypic-negative controls were used.
Progenitor colony-forming assay
The assay for CFU-GEMM, BFU-E and CFU-GM was performed as described in details elsewhere. 24 Briefly, MNC and CD34 + cells were plated in 35-mm petri dishes in 1-ml aliquots of IMDM containing 30% FBS, 5 × 10 −5 M 2-mercaptoethanol, and 1.1% (w/v) methylcellulose. Cultures were stimulated with a mixture of human recombinant colonystimulating factors (CSFs), including IL-3 (10 ng/ml; Amgen, Thousand Oaks, CA, USA), granulocyte-CSF (G-CSF; 10 ng/ml; Amgen), GM-CSF (10 mg/ml; Behringwerke, Marburg, Germany), and erythropoietin (Epo 1 U/ml; Amgen), with or without the addition of SCF (50 ng/ml; Amgen). Progenitor cell growth was evaluated after incubation (37°C, 5% CO 2 ) for 14 days in a humidified atmosphere. Four dishes were set up for each individual data point per experiment. CFU-GEMM, contained both erythroid and granulocytic cells, BFU-E contained у500 cells, and CFU-GM contained у40 cells and were all scored from the same plates.
Mafosfamide treatment MNC cells (n = 11) were counted, their concentration adjusted to 2 × 10 7 /ml and then divided into five aliquots which were incubated with several concentrations of freshly diluted mafosfamide (Asta Medica, Biefeld, Germany) ranging from 40 to 220 g/ml. Each sample was incubated (30 min, 37°C) in a water bath with frequent agitation. Then the cells were incubated for 5 min in ice-cold water to stop the reaction, washed twice, resuspended in Iscove's modified Dulbecco's medium (Biochrom KG, Berlin, Germany) and cultured with a standard mixture of CSFs, with or without the addition of SCF, to quantitate CFU-GEMM, BFU-E and CFU-GM. As control, we tested by the same conditions BM MNC cells (n = 7) obtained from consenting healthy adult volunteers by aspiration from the posterior iliac crest.
Single colony-transfer assay
Mafosfamide-untreated and -treated cells (n = 7), were plated in methylcellulose with IL-3, G-CSF, GM-CSF and Epo in the absence or presence of SCF. On day 14 of primary culture single, well isolated colonies, were picked up in a volume not greater than 5 l, transferred to an individual well of a 96-well tissue-culture plate (Costar, Cambridge, MA, USA) containing 0.1 ml of IMDM supplemented with 20% FBS, and dispersed into a single-cell suspension by gentle pipetting. Complete resuspension was verified by optical examination. Each cell suspension was then plated in methylcellulose culture medium into an individual well of a 12-well tissue-culture plate (Costar). Secondary cultures stimulated with IL-3, GM-CSF, G-CSF and Epo were incubated for 14 days and scored for colonies.
Statistical analysis
Statistical analysis was performed with the statistical package Statview (BrainPower, Calabasas, CA, USA) run on a Macintosh LC II personal computer (Apple Computer). The Student's t-test for paired data was used to test for significance of changes in the comparison of data involving counts. The Wilcoxon signed-rank test was used to test for significance of changes in the incidence of progenitor cells grown from untreated and mafosfamide-treated samples.
Results
Isolation of CD34-positive cells Enrichment of CD34
+ cells was successfully accomplished by means of a magnetic cell sorting procedure. The final yield of CD34 + cells was 60.8 ± 4%, with a CD34 purity of 89.6 ± 6.5%. The procedure resulted in a 32.2-fold enrichment of CFC; in fact the number of colonies per 0.5 × 10 5 cells plated was 57.5 ± 21.9 for unseparated cells, and 1855 ± 134 for CD34
+ cells.
Expression of growth factor receptors
To characterize further the CD34 + population, surface receptors for the hematopoietic growth factors, SCF, IL-3, GM-CSF, were analyzed using flow cytometry. SCF receptors were expressed on 94.4 ± 6.1% of CD34 + cells, while receptors for IL-3 and GM-CSF were present on 39.4 ± 7.3% and 47.0 ± 8.1% of CD34 + cells, respectively. Figure 1 shows representative fluorescence histograms from one experiment. Fluorescence with the bound growth factor appeared as a single, distinct peak. Specificity of binding of the biotinylated cytokine was confirmed by inhibition of binding in the presence of an excess of unlabelled growth factor (data not shown). Growth factor receptor distribution on UCB CD34 + cells. The white area represents the control fluorescence, the dark area represents fluorescence using the indicated biotinylated growth factor conjugate. The X axis plots fluorescence intensity, the Y axis relative cell number. Figure 2 . 1188 ± 104*** CFU-GEMM, BFU-E and CFU-GM are expressed as number of colonies per 5 × 10 4 cells plated. Cultures in methylcellulose were stimulated with IL-3 (10 ng/ml), G-CSF (10 ng/ml), GM-CSF (10 ng/ml), Epo (1 U/ml), and with or without SCF (50 ng/ml). *P р 0.0005; **P р 0.025, ***P р 0.005; a NS.
Effect of SCF on colony formation
MNC and CD34 + cells from UCB were stimulated maximally with a combination of G-CSF, GM-CSF, IL-3, Epo and with or without a predetermined optimal concentration of SCF (50 ng/ml). The effect of SCF on colony formation of CFU-GEMM, BFU-E and CFU-GM is shown in Table 2 . SCF significantly increased colony formation of CFU-GEMM and CFU-GM both in the MNC and in the CD34 + cell population. Only erythroid growth was not enhanced by the presence of SCF and this was accounted for by a more prominent increase in mixed cell colonies. Moreover the presence of SCF not only increased the number but also the size of colonies (data not shown).
Effect of mafosfamide treatment
We tested UCB (n = 11) and BM (n = 7) MNC cells to determine the resistance to mafosfamide treatment. When MNC cells were incubated with increasing doses of mafosfamide a significantly dose-dependent suppression of CFU-GEMM, BFU-E and CFU-GM growth was observed. Figure 3 shows the mean ± s.d. concentrations of mafosfamide (g/ml) needed to inhibit 95% of UCB colonies growth (ID 95 ). The addition of SCF significantly increased the mean ± s.d. ID 95 value for
Figure 3
Concentration of mafosfamide (g/ml) inducing 95% inhibition of colonies growth (ID 95 ). Results are expressed as mean ± s.d. (n = 11). Cultures were set up in methylcellulose and stimulated with a standard mixture of cytokines (IL-3, G-CSF, GM-CSF, Epo), with or without the addition of SCF (50 ng/ml). *P р 0.05; **P р 0.005. CFU-GEMM (174 ± 20.1 vs 125.5 ± 10.6, P р 0.05) and CFU-GM (201 ± 12.9 vs 135 ± 13.4, P р 0.005), but not for BFU-E (185.2 ± 18.6 vs 128.6 ± 12.5, P р 0.375). In comparison the mean ± s.d. ID 95 values (g/ml) for BM MNC cells were 86 ± 2.2, 90 ± 5.8, 106 ± 17 for CFU-GEMM, BFU-E and CFU-GM, respectively, in the absence of SCF; while in the presence of SCF the same figures were 90.5 ± 1.9 (P р 0.375), 92.5 ± 4.8 (P р 0.375), 130 ± 29 (P р 0.0005) for CFU-GEMM, BFU-E and CFU-GM, respectively.
Replating potential
The replating capability of untreated and mafosfamide-treated cells, grown in primary cultures in the absence or presence of SCF, was tested as a potential measure of self-renewal. Replating potential was determined as the percentage of primary colonies giving rise to at least one secondary colony. In Figure 4 the results of seven paired experiments for untreated and mafosfamide-treated cells show that primary colonies cultured in the presence of SCF have a significantly higher potential for initiation of secondary cultures for both untreated (42 ± 3.3% vs 21 ± 4.6%, P р 0.018) and mafosfamide-treated (62 ± 5.6% vs 44 ± 6.1%, P р 0.018) samples. Moreover, the mean ± s.d. number of secondary colonies derived per each replated colony, initiated from untreated cells without or with SCF, was 4.7 ± 3.5 and 12.6 ± 5.3 (P р 0.005), respectively. The same figures for mafosfamide-treated cells were 7.9 ± 4.2 and 23.2 ± 9.6 (P р 0.005), respectively.
Discussion
Ontologically, hematopoiesis during embryonic and fetal development is represented as a migratory phenomenon 25 that reaches the BM as the final step. Fetal blood immediately prior to delivery has been shown to contain hematopoietic progeni-
Figure 4
Replating efficiency of untreated and mafosfamidetreated MNC cells (n = 7). Primary cultures were stimulated with a standard combination of CSFs (IL-3, G-CSF, GM-CSF, Epo), in the absence or presence of SCF. Secondary cultures were stimulated with a standard combination of CSFs. The replating efficiency was determined as the percentage of primary colonies giving rise to at least one secondary colony. tor cells at similar or higher frequency than that of BM. 1, [7] [8] [9] 12 Therefore, UCB, which is normally discarded, has been evaluated as a source of progenitor cells that can be used for the treatment of diseases potentially curable by bone marrow transplantation (BMT). [2] [3] [4] Major concerns for wider transplant application of UBC have been related to the low total number of progenitor cells obtained by a single collection. Therefore, many attempts are ongoing better to understand the biologic and immunologic characteristics of UCB progenitor cells and to evaluate potential for their ex vivo expansion. [7] [8] [9] 11 The structural and functional integrity of the hematopoietic system is maintained by a relatively small population of stem cells that undergo self-renewal. 26, 27 Unfortunately, in vitro assays are not available for identifying pluripotential stem cells because of immense heterogeneity within the stem and progenitor cell compartments. Therefore, surrogate assays for identifying primitive hematopoietic cells include expression or absence of specific cell surface antigens (CD34, HLA-DR, CD38, CD71, CD45RA, Thy-1), resistance to 4-hydroperoxycyclophosphamide or mafosfamide treatment, ability to initiate long-term culture (LTC-IC), or appearance as high proliferative potential colony-forming cells (HPP-CFC) in shortterm culture. Data on the content of CD34
+ cells indicate a similar frequency of CD34 + cells in BM and UCB. 21, 28 Nevertheless, CD34
+ cells with an immature phenotype (CD38
) appear in greater frequency in UCB in comparison to BM. 12 The CD34 + CD38 − immunophenotype defines a rare, quiescent and functionally primitive population of progenitor cells, both in BM and UCB. However, CD34 + CD38 − UCB cells have been reported to possess a higher cloning efficiency, to proliferate more rapidly in response to cytokine stimulation and generate approximately seven-fold more progeny than their BM counterparts. 29 Based on double-fluorescence staining of purified CD34 + cells, our results confirm that more CD34 + UCB cells lack the expression of CD38 antigen. The more primitive nature of UCB progenitor cells is also sustained, as we report, by the high frequency of cells which are CD34
+ but negative for CD45RA. 30 Moreover, a primitive subpopulation of CD34 + BM cells and containing up to 42% of multipotent progenitor cells. 12 However, in contrast to adult BM, in which the primitive progenitor cells reside in the HLA-DR − compartment, the majority of UCB primitive progenitor cells are detected in the HLA-DR + fraction. In fact, a nine-fold increase in HPP-CFC and a three-to six-fold increase in BFU-E and CFU-GM after LTC in the HLA-DR + fraction in comparison to the HLA-DR − counterpart has been reported. 31 The immunophenotypic characteristics of immaturity of UCB progenitor cells are also confirmed by in vitro studies indicating a functional immaturity of UCB progenitor cell compartments. 12 Our previous 32 and present results are consistent with other reports 9, 12, 29 in showing a higher clonogenic capacity and replating potential of UCB progenitor cells in comparison to BM. In this respect, resistance to cyclophosphamide derivatives has been described as a further characteristic of stem cells. In humans, BM treatment with cyclophosphamide derivatives has been shown to deplete committed progenitors while preserving stem cells capable of hematopoietic recovery. 33 By comparing ID 95 values of UCB progenitor cells to those of normal BM, it is clearly evident that UCB progenitor cells are more resistant to mafosfamide treatment. In addition, ID 95 values were significantly increased by the presence of SCF, indicating that SCF induces early hematopoietic progenitor cells, that are resistant to mafosfamide treatment, to proliferate. Moreover, we have shown that mafosfamide-treated UCB progenitor cells, cultured in the presence of SCF, posses a significantly higher replating potential in comparison to either untreated or mafosfamide-treated progenitor cells, grown in the absence of SCF.
Recent data, on UCB transplantation into unrelated recipients, have suggested a correlation of the dose of reinfused cells with the rate of recovery. 4 Therefore, many attempts are ongoing to evaluate the possibility of expanding UCB progenitor cells [7] [8] [9] 11 and SCF in combination with other CSFs has been proven as a relevant factor for amplification of those cells capable of hematopoietic engraftment. SCF has been reported to act in combination with a variety of CSFs to influence the development of early hematopoietic progenitor cells. 7, 14 Results reported here confirm that SCF in combination with other CSFs significantly increases the growth of progenitor cells (CFU-GEMM, CFU-GM) from both MNC and CD34
+ cells and promotes a significantly higher replating efficiency, as previously described. 34 The relevance of CSFs for hematopoietic regulation is supported by the presence of specific CSF receptors on progenitor cells and therefore the expression of early acting CSFs receptors can be a useful tool for stem cell identification. Several studies indicate that the ckit molecule is expressed on primitive progenitor cells and plays an essential role in murine and human hematopoiesis. 14, 15 Therefore, studies of SCF receptor are essential for understanding the regulatory processes in hematopoiesis. In mice, it has been reported that 70-80% of Thy-1 + Sca + Lin − cells express c-kit, and by separation into c-kit + and c-kit − cells, only the c-kit + cells led to the production of donorderived cells in irradiated mice. 35 Analogous studies have been reported for the human stem cell population, showing that the c-kit + cells were 400-fold enriched in progenitor cells 17 and that the c-kit + fraction of CD34 + HLA-DR − cells, but not the c-kit − counterpart, was able to generate hematopoietic progenitor cells for up to 10 weeks. 36 A stage-related expression of c-kit protein has been demonstrated in murine, 18 and more recently in human BM progenitor cells. 19 In fact, the LTC-IC content was reported to be higher in BM-derived CD34 + c-kit low cells than in CD34 + c-kit high cells, and that the latter population derives from the former after long-term culture on stromal cells. 19 In addition, by using monoclonal antibody to c-kit, UCB primitive progenitor cells have been reported to reside in the c-kit low population, while in contrast, the maturer reside in the c-kit high counterpart. 37 We have examined the receptors for SCF on UCB selected CD34 + cells by means of direct cytokine binding to cells. Although the method used in our study is not able to determine the actual number of receptors, it can be used to characterize the relative numbers of receptors on selected cells; however, by measuring direct growth factor binding, we were able to detect alternative receptors also, that may be missed by other procedures in which specific antibodies are used to detect growth factor receptors indirectly. We detected SCF receptor in all UCB CD34 + cells. In addition, since the majority of the more immature progenitor cells in UCB are reported to reside in the CD34 +
HLA-DR
+ fraction, 31 we have further studied, by means of three-color analysis, the expression of SCF receptors on this specific subset. Two subpopulations expressing the receptors at low and high intensity were identified, and the majority of CD34 +
+ cells were present in the SCF low fraction. Previous studies reported that dormant murine and human BM primitive progenitors are c-kit low , 18, 38 and that UCB 
KIT
low cells respond to anti-TGF-␤ serum by an upmodulation of c-kit mRNA, proving that SCF can stimulate the earliest CD34 + cells only if anti-TGF-␤ serum or antisense oligonucleotides have blocked the autocrine TGF-␤ that downmodulates c-kit. 39, 40 However, further analysis on CD34 + HLA-DR + progenitor cells sorted by the high or low expression of SCF receptors needs to be performed in order to elucidate clearly the role of the c-kit molecule in the identification of primitive progenitors. These studies will allow a more appropriate evaluation of the biologic characteristics and hematopoietic potentials of ex vivo expanded progenitor cells.
